API | rolofylline

rolofylline Report issue

Small molecule Experimental

AACT ChEMBL DrugBank MeSH PubChem

Active Ingredient History

NOW

Rolofylline (KW-3902) is an experimental diuretic which acts as a selective adenosine A1 receptor antagonist. It was discovered at NovaCardia, Inc. which was purchased by Merck & Co., Inc. in 2007. ^Wikipedia

Chemistry

SMILES: CCCN1C(=O)N(CCC)c2[nH]c(nc2C1=O)C34CC5CC(CC3C5)C4
InChIKey: PJBFVWGQFLYWCB-UHFFFAOYSA-N
Mol. Mass: 356.47
ALogP: 2.78 Partition coefficient
ChEMBL Molecules:

rolofylline

None

More Chemistry

Pharmacology

Mechanism of Action:
- Adenosine receptor A1 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

1,3-dipropyl-8-(3-noradamantyl)xanthine | 1,3-dnax | 8-(3-noradamantyl)-1,3-dipropylxanthine | 8-(noradamantan-3-yl)-1,3-dipropylxanthine | kw 3902 | kw-3902 | mk7418 | mk 7418 | mk-7418 | rolofylline

Organizations (5)

Research & Development (5)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (3)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (3)

Heart Failure (Phase 3)

Kidney Failure, Chronic (Phase 2)

Renal Insufficiency (Phase 2)

Overview

Highest Phase: Phase 3
# of Trials: 7
# of Trial Organizations: 5

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue